. Author manuscript; available in PMC: 2014 Oct 30.

Published in final edited form as: J Nucl Med. 2012 Jun 11;53(7):1110–1118. doi: 10.2967/jnumed.111.100842

TABLE 1.

Biodistribution of ¹⁸F-FBEM-Cys-Z_EGFR:1907 in Nu/ν-Mice Bearing Subcutaneously Xenotransplanted A431 with Spiked Dose (Ac-Cys-Z_EGFR:1907)

Organ	Dose (μg)
Organ	0	45	500, block
Tumor	3.94 ± 0.39^†	8.06 ± 1.44^†^*	0.97 ± 0.42^*
Blood	3.75 ± 0.12^†	3.12 ± 0.10^†^*	0.12 ± 0.03^*
Heart	0.79 ± 0.04	0.71 ± 0.05^*	0.06 ± 0.02^*
Liver	9.28 ± 1.61^†	6.50 ± 0.31^†^*	0.33 ± 0.15^*
Lungs	1.54 ± 0.10	1.87 ± 0.32^*	0.14 ± 0.07^*
Muscle	0.32 ± 0.05	0.23 ± 0.05^*	0.02 ± 0.01^*
Kidney	3.78 ± 0.36^†	4.75 ± 0.14^†	6.14 ± 2.87
Spleen	0.61 ± 0.03	0.51 ± 0.07^*	0.15 ± 0.07^*
Brain	0.18 ± 0.07	0.14 ± 0.01^*	0.01 ± 0.01^*
Intestine	1.02 ± 0.27	0.75 ± 0.14^*	0.37 ± 0.37^*
Skin	1.12 ± 0.48	1.10 ± 0.10^*	0.08 ± 0.05^*
Stomach	1.16 ± 0.14^†	0.71 ± 0.10^* ^†	0.06 ± 0.03^*
Pancreas	0.56 ± 0.42	0.52 ± 0.02^*	0.04 ± 0.01^*
Bone	0.31 ± 0.23	0.41 ± 0.09^*	0.12 ± 0.04^*
Uptake ratio
Tumor to blood	1.05 ± 0.08^†	2.58 ± 0.47^†^*	7.76 ± 1.29^*
Tumor to lung	2.56 ± 0.120	4.32 ± 0.35^†^*	7.26 ± 0.43^*
Tumor to muscle	12.80 ± 3.32^†	36.88 ± 12.77^†	40.29 ± 2.70

P < 0.05, comparison of biodistribution between probe spiked with 45 and 500 μg (blocking dose) of Ac-Cys-Z_EGFR:1907 at 3 h after injection.

^†

P < 0.05, comparison of biodistribution between probe spiked with 0 and 45 μg of Ac-Cys-Z_EGFR:1907 at 3 h after injection.

Data are mean ± SD, expressed as percentage administered activity (injected probe) per gram of tissue (%ID/g) after intravenous injection of probe (1.85–2.59 MBq [50–70 μCi], ~2–3 μg) spiked with 0, 45, and 500 μg of Ac-Cys-Z_EGFR:1907 at 3 h after injection. Significant inhibition of ¹⁸F-FBEM-Cys-Z_EGFR:1907 uptake was observed in A431 tumor of blocked group (500 μg) (P < 0.05).